In Vitro and in Vivo evaluation of transdermal absorption of naproxen sodium

Australian Journal of Basic and Applied Sciences

Volumn 3, Issue 3, 2009, Pages 2154-2165

  Attia, Dalia A ^a  

^a Al Azhar University   (Egypt)

Author keywords

In vitro; In vivo; Naproxen sodium; Transdermal absorption

Indexed keywords

EID: 77952267491     PISSN: 19918178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Beetge, E., J. du Plessis, D.G. Müller, C. Goosen, van F.J. Rensburg, 2000. The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption. Int. J. Pharm., 193: 261-264.
2. Berba, J., S. Goranson, J. Langle, U.V. Banakar, 1991. In vitro release of selected nonsteroidal anti-inflammatory analgesics from reservoir type transdermal formulations. Drug Dev. Ind. Pharm., 17: 55-65.
3. Bonina, F.P., C. Puglia, T. Barbuzzi, P. De Caprariis, F. Palagiano, M.G. Rimoli, A. Saija, 2001. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur. J. Pharm. Sci., 14: 123-134.
4. Capone, M.L., S. Tacconelli, M.G. Sciulli, et al. 2007. Human pharmacology of naproxen sodium. Pharmacol. Exp. Ther. 322: 453-460.
5. Chi, S.C. and H.W. Jun, J. Pharm. Sci., 1990. 79: 974.
6. Cioli, V., S. Putzolu, V. Rossi, P. Borcellona and C. Corradino, 1979. The role of direct tissue contacr in the production of gastrointestinal ulcers by anti-inflammatory drugs in rats. Toxicol.Appl.Pharmacol., 50: 283-289.
7. Finnin, B.C., T.M. Morgan, 1999. Transdermal penetration enhancers: applications, limitations, and potential. J. Pharm. Sci., 88: 955-958.
8. Godwin, D.A., B.B. Michniak, 1999. Influence of drug lipophilicity on terpenes as transdermal penetration enhancers. Drug. Dev. Ind. Pharm., 25: 905-915.
9. Hadgraft, J., 1999. Passive enhancement strategies in topical and transdermal drug delivery, Int. J. Pharm., 184: 1-6.
10. Hadgraft, J., 1989. Formulation of anti-inflammatory agents. In: N.J. Lowe and C.N. Hensby (Eds). Non-Steroidal Anti-Inflammatory Drugs, 21-43.
11. Hadgraft, J. and G. Ridout, 1988.Development of model membrane for percutaneous absorption measurement by dipalmitoyl phosphatidylcholine, Linolic acid and tetradecane. Int. J. Pharm., 42: 97-104.
12. Hsu, L.R., Y.B. Huang, P.C. Wu, Y.H. Tsai, 1994. Effect of the administration of ketoprofen gel on the percutaneous absorption of ketoprofen in rabbits. Drug Dev. Ind. Pharm., 20(6): 1093-1101.
13. Hui, X., R.C. Wester, H. Zhai, H.I. Maibach, 2005. Chemical partitioning into powdered human stratum corneum: a useful in vitro model for studying interaction of chemicals and human skin, in: R.L. Bronaugh, H.I. Maichach (Eds.), Percutaneous Absorption, Taylor & Francis, Boca Raton, 291-302.
14. Jacobi, U., T. Tassopoulos, C. Surber, J. Lademann, 2006. Cutaneous distribution and localization of dyes affected by vehicles all with different lipophilicity. Arch. Dermatol. Res., 297: 303-310.
15. Jose Antonio Palma-Aguirre, PhOl; Jorge Villalpando-Hernandez, MOl; German Novoa-Heckel, MOl; Ivan Oliva, MS2; Lizbeth Carino, MS2; Ericka Löpez-Bojörquez, MS2; Victoria Burke-Fraga, BS2; Salvador Namur, MS2; and Mario Gonzalez-de la Parra, Pho2. 2009. Bioavailability of Two Oral-Tablet and Two Oral-Suspension Formulations of Naproxen Sodium/Paracetamol (Acetaminophen): Single-Dose, Randomized, OpenLabel, Two Period Crossover Comparisons in Healthy Mexican Adult Subjects. Clinical Therapeutics/Volume 31, Number 2.
16. Junginger, H.E., J.C. Verhoef, 1998. Macromolecules as safe penetration enhancers for hydrophilic drugs-a fiction, PSTT, 370-376.
17. Kormeyer, R.W., R. Gurny, E. Doelker, P. Buri, N.A. Peppas, 1983. Mechanisms of solute release from porous hydrophilic polymer. Int. J. Pharm., 15: 25-35.
18. Marzouk, A.M., 1999. PhD thesis, Cairo University, Egypt.
19. Moyer, S., 1986. Pharmacokinetics of naproxen sodium. Cephalalgia. 6(SuppI4): 77-80.
20. Niazy, E.M., 1996. Differences in penetration-enhancing effect of Azone through excised rabbit, rat, hairless mouse, guinea pig and human skins, Int. J. Pharm., 130: 225-230.
21. Okamoto, H., H. Komatsu, M. Hashida and H. Sezaki, 1986. Effect of bet-cyclodextrin and di-o-beta-cyclodextrin on the percutaneous absorption of butyl paraben, Indomethacin and Sulfanilic acid. Int.J.Pharm, 30: 35-45.
22. Ozawa, Y., T. Yamahira, H. Sunada, T. Nadai, 1988. Influence of fatty acid-alcohol esters on percutaneous absorption of hydrocortisone butyrate propionate. Chem. Pharm. Bull., 36: 2145-2151.
23. Peppas, N.A., 1985. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta Helv. 60: 110-111.
24. Pharmaceutical excepient, 2003, Fifth edition, Edited by Raymond C., Rowe, Paul J. Sheskey and Siân C., Owen.
25. Potts, R.o. and M.L. Francoeur, 1990. Biophysics of water loss through the skin. Proc.natt.Acad.Sci USA, 87: 3871-3873.
26. Rautio, J., H. Taipale, J. Gynther, J. Vepsaelaeinen, T. Nevalainen, T. Jaervinen, 1998. In vitro evaluation of acyloxyalkyl esters as dermal prodrugs of ketoprofen and naproxen. J. Pharm. Sci., 87: 1622-1628.
27. Ritger, P.L., N.A. Peppas, 1987a. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Rel., 5: 23-36.
28. Ritger, P.L., N.A. Peppas, 1987b. A simple equation for description of solute release.II. Fickian and anomalous release from swellable devices. J. Control. Rel., 5: 37-42.
29. Sastry, M.S.P., P. Rama Rao, P.V. Diwan, 1995. Percutanous absoprtion of naproxen from different ointment bases in rats. Indian Journal of Pharmacology, 27: 130-132.
30. Sato, K., K. Sugibayashi, Y. Morimoto, 1988. Effect and mode of action of aliphatic esters on the in vitro skin permeation of nicorandil. Int. J. Pharm., 43: 31-40.
31. Scheuplein, R.J., 1978. Site variations in diffusion and permeability, in: A. Jarret (Ed.), The Physiology and Pathophysiology of Skin, Academic Press, New York, 1693-1730.
32. Schier, D.S., S. Moniot, M.I. Gluckman and R.B. Gilbertsen, 1986. J. Pharm. Pharmacol, 39: 57.
33. Schoafer-Korting, M., W. Mehnert, H.C. Korting, 2007. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev., 59: 427-443.
34. Segre, E.J., Naproxen sodium (Anaprox): 1980. Pharmacology, pharmacokinetics and drug interactions. Reprod Med.; 25(SuppI4): 222-225.
35. Sevelius, H., R. Runkel, E. Segre, S.S. Bloomfield, 1980. Bioavailability of naproxen sodium and its relationship to clinical analgesic effects. Br. Clin Pharmacol, 10: 259-263.
36. Swart, H., J.C. Breytenbach, J. Hadgraft, J. du Plessis, 2005. Synthesis and transdermal penetration of NSAID glycoside esters. Int. J. Pharm., 30: 71-79.
37. Teichmann, A., S. Heuschkel, U. Jacobi, G. Presse, R.H.H. Neubert, W. Sterry, J. Lademann, 2007. Comparison of stratum corneum penetration and localization of a lipophilic model drug applied in an o/w microemulsion and an amphiphilic cream. Eur. J. Pharm. Biopharm, 66: 159-164.
38. Valenta, C., M. Wanka, J. Heidlas, 2000. Evaluation of novel soyalecithin formulations for dermal use containing ketoprofen as model drug. J. Control. Release., 63: 165-173.
39. ® through excised rabbit skin and human skin. Int. J. Pharm., 145: 215-220.
40. Yamada, M., and Y. Uda, 1987. Enhancement of percuatenous absorption of molisidomine. Chem. Pharm. Bull., 3390-3398.